AGM
DMAAR

Alpine Global Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Alpine Global Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.9K Hold
362,500
– – ﹤0.01% 211
2025
Q4 		$67.9K Hold
362,500
– – 0.01% 298
2025
Q3 		$78.8K Buy
+362,500
New +$67.4K 0.02% 158

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Alpine Global Management's DMAAR Position: Q1 2026 in Review

Alpine Global Management held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q1 2026 at 362,500 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #211.

Alpine Global Management first reported a position in DMAAR in Q3 2025 and has held it in 3 quarters since. The position peaked at $78.8K in Q3 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • Alpine Global Management held 362,500 shares of Drugs Made In America Acquisition Corp Rights worth $21.9K as of Q1 2026.
  • Alpine Global Management left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q1 2026.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Alpine Global Management's portfolio in Q1 2026, its #211 holding.
  • Alpine Global Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q3 2025 and has held it in 3 quarters since.
  • Alpine Global Management's Drugs Made In America Acquisition Corp Rights position peaked at $78.8K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Alpine Global Management's 13F filing for Q1 2026, filed 15 May 2026.